Effect of Quercetin in Prevention and Treatment of Oral Mucositis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01732393 |
Recruitment Status :
Completed
First Posted : November 22, 2012
Last Update Posted : December 5, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chemotherapy Induced Oral Mucositis | Drug: oral quercetin capsules Drug: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 20 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effect of Quercetin in Prevention and Treatment of Chemotherapy Induced Oral Mucositis in Blood Dyscrasias |
Study Start Date : | January 2010 |
Actual Primary Completion Date : | October 2011 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: oral quercetin capsules
Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
|
Drug: oral quercetin capsules
10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis. |
Placebo Comparator: oral placebo capsules
Patients in the placebo group received two placebo capsules containing lactose .
|
Drug: Placebo |
- lower grade of mucositis [ Time Frame: 3 weeks ]grade of mucositis due to WHO criteria
- duration of mucositis [ Time Frame: 3 weeks of study tiem span and after trial ]duration of mucositis due to Who criteria

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 40 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patient under chemotherapy
- for a hematologic malignancy
- the hematologist permits the trial on the patient
- agreement of patient for participating in the trial
Exclusion Criteria:
- presence pf ANY oral lesion at the beginning of the trial
- loss of follow up
- use of digoxin and cyclosporine
- patient death

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01732393
Iran, Islamic Republic of | |
Oral Medicine Department of Mashhad dental School | |
MAshhad, Khorasan Razavi, Iran, Islamic Republic of, 91735-498 |
Study Director: | Pegah Mosannen Mozafari, assistant professor | Mashhad University of Medical Sciences |
Responsible Party: | Pegah Mosannen Mozafari, assistant professor of oral medicine, Mashhad University of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT01732393 |
Other Study ID Numbers: |
89470 |
First Posted: | November 22, 2012 Key Record Dates |
Last Update Posted: | December 5, 2012 |
Last Verified: | December 2012 |
Quercetin Chemotherapy Mucositis Hematologic Malignancies |
Mucositis Stomatitis Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Mouth Diseases |
Stomatognathic Diseases Quercetin Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs |